We reported previously that the abnormally augmented expression of connexin 26 (Cx26) is responsible for the enhanced spontaneous metastasis of mouse BL6 melanoma cells, and that the exogenous expression of a dominant negative form of Cx26 inhibits the spontaneous metastasis of BL6. Here we show that daily intraperitoneal (i.p.) injections of oleamide, a sleep-inducing lipid hormone, weakly inhibited the spontaneous metastasis of BL6 cells. To obtain a more effective reagent, 19 oleamide derivatives were chemically synthesized and tested for their ability to inhibit the gap junction-mediated intercellular communications (GJIC) that are formed between HeLa cells by the ectopic expression of Cx26 or Cx43. One of these, denoted metastasis inhibitor-18 (MI-18), inhibited the GJIC formed by Cx26 as well as oleamide but unlike oleamide, which is a non-selective inhibitor of connexin, it did not inhibit the GJIC formed by Cx43. Daily i.p. injections of MI-18 potently blocked the spontaneous metastasis of BL6 cells down to 15% of that in the untreated control mice. MI-18 was safe because even after 47 weeks of daily injections, the survival rate of the mice was 93%. We propose that MI-18 may serve as a novel and clinically important prototype of a potent inhibitor of spontaneous metastasis.
Introduction
One of the most important hallmarks of malignant melanoma is its propensity for metastasis. Mouse models in which mice are injected with melanoma cells have served as excellent in vivo model systems that have aided the identification of molecules that could be targeted in anti-metastatic therapies (1) . To develop anti-metastatic drugs for clinical usage, it is important to distinguish between experimentally induced and spontaneous metastases in the mouse models because the metastasis of cancer patients occurs via the latter mechanism.
An excellent experimental system that helps us to understand the differences between experimental and spontaneous metastases involves two sublines of the B16 mouse melanoma cell line, namely, the F10 and BL6 sublines. Both sublines metastasize after i.v. injection (experimental metastasis) but only the BL6 cells will metastasize when the cells are implanted in the footpad (spontaneous metastasis) (2--4). Despite considerable research, it was not clear until recently which gene(s) is responsible for the potent spontaneous metastatic ability of BL6. In our previous study, we performed cDNA library subtraction (5, 6) and found that the augmented expression of the connexin 26 (Cx26) (GJB2) gene is responsible for the high spontaneous metastasis of BL6 (7) . We showed that ectopic over-expression of the Cx26 gene in the F10 cells caused them to spontaneously metastasize to similar levels as BL6. Moreover, we demonstrated that inhibiting Cx26 by introducing its dominant negative form (8) into BL6 cells inhibited the ability of these cells to spontaneously metastasize. The degree of inhibition observed was directly proportional to the levels of the ectopically expressed dominant negative form.
Cx26 is a member of a multigene family that is composed of 420 highly conserved proteins that form the transmembrane channels called gap junctions (or connexons). These proteins mediate the transfer of small molecules and ions between the cytoplasms of adjacent cells in the body (9) . These different connexins can have distinct or overlapping functions depending on the level of their expression in various tissues and cells (10) . Abnormalities in these proteins are responsible for a variety of human diseases (11, 12) . Germline missense mutations in the Cx26 gene have been found to be the cause of hereditary non-syndromic sensorineural deafness and syndromic forms of hearing loss that are associated with palmoplantar keratoderma (13, 14) . Cx26 also plays a role in down-regulating growth and is considered to be a tumor suppressor gene (15, 16) . Supporting this notion is that the down-regulation of Cx26 expression is often observed in tumors and transformed cell lines such as endometrial cancers (17) , hemangiopericytomas (18) , esophageal tumors (19) , bladder cancer (20) , a carcinogen-induced hepatic tumor (21) , hepatocyte HEPG2 cells (22) and prostate cancer cells (23) . The potential role of gap junction-mediated intercellular communications (GJIC) to metastasis was also reported (24) .
Our previous report proposes that Cx26 bears a third function, namely, it promotes the spontaneous metastasis of melanoma cells when its expression is increased (7) . This augmented expression of Cx26 is not only observed in BL6 cells but also in the invasive population of clinical human melanoma cells (7) . Moreover, clinical samples of highly metastatic breast cancer cells (25) and lung squamous cell carcinomas (Ito et al., unpublished observations) also show enhanced Cx26 expression. This function of Cx26 is not necessarily inconsistent with its putative tumor suppressor role, because the expression of Cx26 in the poorly metastatic portion of the clinical tumor samples is reduced (7). Thus, it appears that Cx26 expression is low on poorly metastatic tumors such as F10 cells but that once Cx26 expression is enhanced, the tumors become highly metastatic, like BL6 cells.
Since the dominant negative form of Cx26 inhibits the spontaneous metastasis of BL6 cells, we reasoned that a chemically synthesized inhibitor of Cx26 is a suitable anti-metastatic reagent. It has been reported that oleamide, an endogenous sleep-inducing lipid hormone, and its derivatives are efficient inhibitors of connexins and reduce GJIC, as determined by the in vitro dye-transfer assay (26, 27) . We speculated that oleamide and its derivatives might also efficiently inhibit Cx26 and be able to block the spontaneous metastasis of BL6 cells. Here we report the development of a novel oleamide-based chemical reagent that specifically inhibits Cx26 in vitro and potently blocks the spontaneous metastasis of BL6 cells in vivo.
Materials and methods
Cells and culture BL6 melanoma cells were kindly provided by Prof. I.J.Fidler (The University of Texas, Houston, TX). HeLa human cervical cancer cells were purchased from the American Type Culture Collection (Manassas, VA). HeLa-Cx26, a HeLa subclone that stably expresses rat Cx26, was constructed previously (8) . All cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (FCS).
Chemical synthesis and spectroscopy
Preparation of metastasis inhibitor-18 (MI-18) was performed as schematically shown in Figure 2 . Briefly, the solution of oleamide derivative (D2) (53 mg, 0.19 mmol) in CH 2 Cl 2 (3 ml) was cooled to 0 C, and m-CPBA (49 mg, 0.23 mmol) was added. The reaction mixture was stirred at room temperature for 3 h and poured into saturated aqueous Na 2 S 2 O 3 . The organic layer was separated, and the aqueous layer was extracted with CH 2 Cl 2 . The combined organic layer was washed with brine, dried over Na 2 SO 4 and concentrated in vacuo. Purification of the residue by column chromatography (AcOEt) yielded MI-18 (54 mg, 96%) as a white solid.
The 1 H NMR spectra were measured at 300 MHz with tetramethylsilane (TMS) as the internal standard at 20--25 C. The 13 C NMR spectra were measured at 75 MHz with TMS as internal standard and at 20--25 C. IR spectra were recorded by a diffuse reflectance measurement of samples dispersed in KBr powder. E.Merck silica gel 60 for column chromatography and E.Merck pre-coated TLC plates, silica gel F 254 , for preparative thin-layer chromatography were used, respectively.
Plasmid construction and transfection
The pCX4bsr vector used here is a modified version of the pCXbsr vector (28) . The pBluescriptII SKþ (Stratagene, La Jolla, CA) plasmid vector that contains the cDNA fragment of the entire coding region of rat connexin 43 (Cx43) between its SpeI and ClaI sites was constructed previously (29) . The Cx43 cDNA was excised from the vector by digestion with NotI and HincII and ligated with the pCX4bsr vector that had been digested with NotI and HpaI. HeLa cells were transfected with the resulting pCX4bsr-Cx43 vector by using the TransFast transfection reagent (Promega, Madison, WI) according to the manufacturer's instructions. After transfection, cells were selected by resistance to blasticidin (3 mg/ml) for 3 weeks to obtain single colonies. One of the stably transformed clones (HeLa-Cx43) was used in the dye-transfer assays.
Dye-transfer assay HeLa-Cx26 or HeLa-Cx43 cells were suspended in DMEM containing 10% FCS just before the assay and plated onto both 6-well plates and cover slips placed at the bottom of 6-well plates. The former cells were used as donors and the latter cells as recipients. The initial plating event was adjusted to yield subconfluent monolayers. On the next day, calcein-AM (gap junction-permeable; Molecular Probes, Eugene, OR) and DiI (gap junction-impermeable; Molecular Probes) were added to the donor cell cultures at concentrations of 4 and 10 mM, respectively, and incubated for 1 h. The doubly labeled donor cells were then trypsinized and washed three times with phosphate-buffered saline. 1000 single donor cells suspended in DMEM containing 10% FCS were gently overlaid onto the unlabeled recipient cells. It took~1 h for the donor cells to settle over the monolayer, and~1.5 h to start transferring the calcein dye to recipient cells. To evaluate the inhibitory effects of chemical agents on dye-transfer, the concentrated agents dissolved in ethanol were added to the culture at 20 mM 1 h after plating the donor cells. In the negative control experiments, only a solvent (ethanol) was added to the culture at a dilution of 1:1000. After culturing for an additional 1 h, the cover slips were placed onto microscope slides so that the cellattached sides were in contact with the slides. No mounting media were used and the cells were observed as soon as possible with a confocal laser-scanning microscope (LSM510; Carl Zeiss, Oberkochen, Germany). The donor cells were identified as those containing the DiI dye (red fluorescence). The transfer of calcein dye (green fluorescence) from the DiI-positive donor cells to the DiInegative recipient cells is termed 'dye coupling'.
The inhibitory effects of the chemical agents on Cx26-and Cx43-mediated GJIC were evaluated by following two methods using HeLa-Cx26 and HeLaCx43 cells. First, to quickly screen the effectiveness of all the newly synthesized agents, each donor cell was scored as either 1 or 0 depending on whether the cell exhibited dye coupling. The total scores of 25 donor cells in the presence of a newly synthesized agent were compared with the scores of donor cells in the absence (0% inhibition) or presence (100% inhibition) of oleamide to determine the percentage of inhibition of dye coupling. Secondly, to more accurately estimate the extent to which the agents inhibit dye coupling, the donor cells were given scores of one to eight as follows. Donor cells were scored as 0 for no dye-coupling, as 1 for dye-coupling from a donor cell to an adjacent recipient cell, as 2 when the adjacent cell transferred calcein to a subsequent adjacent cell in a direction away from the donor cell, as 3 when the transfer was to a third cell away from the donor cell, and so on. Dye transfer to eight or more cells away from the donor cell was scored as 8, although this was sometimes difficult to evaluate. Scoring was performed for at least 30 donor cells per agent group on the condition that the donors were single cells that were at least 20 cells away from other donor cells. The mean and standard deviation (SD) of the score counts were calculated for each agent group and expressed as GJIC scores. Differences among the agent groups were examined by the unpaired Student's t-test, and a P value of 50.05 was considered to be significant. Experiments were repeated three times, with similar results.
Spontaneous metastasis assay 2.5 Â 10 5 BL6 cells were injected subcutaneously into the one footpad of each 4-week-old male C57BL/6 mice (15 mice/reagent). Oleamide (25 mg/kg of mouse) or MI-18 (10 mg/kg of mouse) was dissolved into olive oil. Except for the Nt control mice, 0.1 ml of saline, oleamide or MI-18 solutions was injected intraperitoneally once every day, starting the day after injecting the BL6 cells into the footpad. This continued until the mice were killed. The growth of the primary tumor was monitored by measuring its diameter every day. Approximately 3--5 weeks later depending on the individual mouse (see Figure 4A) , when tumors reached a diameter of 7 mm, the tumor-bearing legs were amputated along with the right popliteal lymph node. After an additional 28 days, the mice were killed and autopsied to count the metastatic colonies in the bilateral lungs and to examine the metastasis to the lymph nodes.
Results

Oleamide inhibits the spontaneous metastasis of BL6 cells
We first assessed the effect of daily i.p. injections of oleamide on the spontaneous metastasis of BL6 cells from their implanted location in the footpad of recipient mice. Mouse BL6 melanoma cells were injected subcutaneously into the mouse footpad and from the next day onwards oleamide was injected intraperitoneally every day. One group of mice did not receive any injections and served as the negative control group (Nt, no treatment), and another group of mice received saline alone (Sa, saline). We allowed BL6 cells to grow in the footpad until the tumor size reached 7 mm in diameter and then amputated the tumor-bearing leg. After monitoring the mice over the following 4 weeks, we killed the mice to examine the extent to which the BL6 cells had metastasized to the lung by counting lung metastasis colony numbers. As shown in Figure 1 , oleamide injection reduced the number of metastatic colonies to 34 and 37% of that in the Nt and Sa control mice, respectively. When we repeated this experiment, oleamide showed a similar inhibitory effect (data not shown). These results suggest that oleamide does inhibit the spontaneous metastasis of BL6 cells, although its inhibitory effect is not sufficient for its direct use as an anti-metastasis drug.
MI-18 specifically inhibited Cx26 in vitro
That oleamide reduced BL6 cell metastasis encouraged us to synthesize new derivatives of oleamide, as some of these may be more potent inhibitors of spontaneous metastasis. The oleamide derivatives were synthesized according to the schemes shown in Figure 2A . We first examined the inhibitory effect of oleamide by our dye-transfer assay using HeLa cells that ectopically express Cx26 or Cx43 (HeLa-Cx26 or HeLaCx43). In this assay, donor HeLa cells were labeled with a gap junction impermeable dye (DiI) plus a gap junction permeable dye (calcein-DM) and then sparsely placed on top of unlabeled recipient HeLa cells. The numbers of recipient cells (DiI-negative) that received calcein-DM were then assessed under a microscope. We found that oleamide inhibits the GJICs that are formed between HeLa cells by the ectopic expression of either Cx26 or Cx43 ( Figure 3A) .
Thereafter, 19 oleamide derivatives were synthesized and screened for their ability to inhibit GJIC (relative to the effect of oleamide) by dye-transfer assays using HeLa-Cx26 cells ( Figure 2B ). The authenticity and purity of the synthesized chemical agents were confirmed by the standard NMR and IR spectroscopy (data not shown). To minimize the possible ability of the agents to block the cell--cell attachments between the donor and recipient cells, the agents dissolved in ethanol were directly added to the culture 1 h after the donor cells had been laid onto the recipient cell monolayer, as most donor cells had already settled onto the recipient cells at this point. The screening of the 19 derivatives revealed that MI-18 showed relatively greater inhibition than the others, and it was as potent as oleamide itself ( Figure 2B) . Moreover, when we examined the recipient cells in the dye transfer assay more closely and applied a score based on how many recipient cells away from each donor cell received the calcein-AM dye from the donor (the GJIC score), we again found that MI-18 inhibited GJIC to the same degree as oleamide ( Figure 3A) .
To examine the specificity of the inhibition mediated by MI-18, we compared its GJIC score in dye-transfer assays using HeLa-Cx26 or HeLa-Cx43 cells. It is important that any agent that is used as an anti-metastatic drug that blocks Cx26 should not be able to block Cx43 function, as it is known that the hereditary absence of cardiac Cx43 results in ventricular arrhythmias and sudden cardiac death (30) . When HeLa-Cx26 cells were used, MI-18 was found to reduce the GJIC scores of Cx26 to the same extent as oleamide ( Figure  3A) . In contrast, dye-transfer assays using HeLa-Cx43 cells revealed differences between oleamide and MI-18 ( Figure 3A and B) , as oleamide reduced the GJIC scores of Cx43 while MI-18 had no effect at all.
MI-18 potently blocks the spontaneous lung metastasis of BL6 cells
We next examined whether MI-18 also inhibits BL6 cells from spontaneously metastasizing to the lung. The day after BL6 melanoma cells were injected subcutaneously into the mouse footpad, MI-18 was injected intraperitoneally every day. As shown in Figure 1 (rightmost column), the MI-18 injections significantly reduced the number of metastatic colonies in the lung to 15% of that in the Nt control mice.
To know if treatment of mice with MI-18 affects the tumor growth in the footpad, we measured the number of days required for the implanted tumors to reach 7 mm in diameter. We noted that MI-18 does not appear to affect the growth of BL6 cells in the footpad since the number of days was similar to the time taken by the Nt, Sa and oleamide-treated mice ( Figure 4A ).
To assess whether the drug treatment was responsible for some mortality, we monitored the mice over the following 4 weeks after amputation of the tumor-bearing leg, whilst continuing the daily treatment injections. MI-18 appears to be quite safe because none of the MI-18-treated mice died in the 3 weeks following the amputation ( Figure 4B ). Even 28 days after the amputation, at which point the mice were killed, 14 of the 15 MI-18-treated mice survived, yielding a survival rate of 93%. The death of the single MI-18-treated mouse that died was due to the metastasis of BL6 rather than to possible toxicity of MI-18. It is not known why this mouse alone did not show any metastatic inhibition of MI-18. In contrast, the survival rates of the Nt, Sa and oleamide-treated mice were 73, 70 and 87%, respectively. The greater survival rate of the MI-18 mice is probably because MI-18 effectively inhibited the metastasis and caused these mice to be healthier.
In Figure 5 , we present photo-images of all the lungs from the Nt control mice and the MI-18-treated mice. The lungs were removed by autopsy at 28 days after amputation when mice were killed. While multiple metastatic colonies were observed in the lungs from the untreated mice, reduced numbers of metastatic colonies were found in the lungs from mice treated with oleamide or MI-18.
MI-18 also inhibits the lymph node metastasis of BL6 cells
It is known that the most common route for the metastatic spread of primary cutaneous melanoma is through the lymphatic vessels (31) . As most of the lymph is eventually returned to the bloodstream, secondary hematogeneous spread of Fig. 1 . Oleamide weakly inhibits and MI-18 potently blocks the spontaneous metastasis of BL6 melanoma cells to the lung. The inhibitory effects of the indicated agents on the number of metastasized colonies in the lungs arising from the BL6 cells implanted in the footpad. The agents were intraperitoneally injected daily the day after BL6 cells were subcutaneously injected into one footpad of each 4-week-old mouse. The spontaneous metastasis assay was performed as described previously (5,7). Nt, no treatment; Oa, oleamide; MI-18, a newly synthesized derivative of oleamide. The Sa group contained 10 mice while the Nt, Oa and MI-18 groups each contained 15 mice. The mean values of the metastatic colony numbers were plotted with bars indicating the SE.
Ã P 5 0.05 by t-test when compared with the value obtained from Nt control group.
Oleamide blocks metastasis melanomas is common. Considering this, we examined the metastasis of BL6 cells to systemic lymph nodes (Table I) . We found that fewer MI-18-treated mice showed metastasis to systemic lymph nodes, especially to the intra-abdominal and pleural lymph nodes, compared with the Nt mice. The mice that were treated with oleamide also showed slight inhibition of the metastasis to the inguinal, intra-abdominal and pleural lymph nodes, although the effects are not as marked as in the MI-18-treated mice. Little or no metastasis was observed in the axillary lymph nodes in all cases, although one oleamide-and two MI-18-treated mice had metastases in their axillary nodes whose physiological significance is unknown. It was notable that the number of melanoma-metastatic lymph nodes decreased with their distance from the primary mass, especially in mice treated with MI-18. These observations indicate that MI-18 also inhibits the metastasis of BL6 cells to the lymph nodes, and suggests that the secondary hematogeneous metastasis of melanoma to the lungs occurs much less frequently in MI-18-treated mice.
Discussion
MI-18 potently blocks the spontaneous metastasis of BL6
In the present study, we show that oleamide inhibits the spontaneous metastasis of BL6 melanoma cells. Moreover, we demonstrate that MI-18, one of the 19 oleamide derivatives synthesized here, also potently blocks the spontaneous metastasis of BL6 cells. We propose that MI-18 may be suitable as the basis for the development of even more potent antimetastatic drugs in the future. MI-18 is more useful in this respect than oleamide because it does not block the Cx43-mediated GJIC, unlike oleamide. The Cx43-mediated GJIC regulates the ventricular pulse. That the Cx43-blocking activity of oleamide could be deleterious is suggested by the fact that the oleamide-treated mice had a poorer survival rate compared with the mice treated with MI-18, despite equivalent tumor burdens. This higher mortality may thus be attributable, at least in part, to the drug-induced ventricular arrhythmias and sudden death that could result from the failure of cardiac Cx43 function (30) . It remains to be determined if MI-18 can inhibit other connexins related to arrhythmias, such as Cx40 or Cx45. For the future drug design, it should be remembered that oleamide and its derivatives are not the specific inhibitors of GJIC and they may also act on other transmembrane channels. The treatments of daily intraperitoneally injection of the agents the day after BL6 cells were subcutaneously injected into one footpad have almost equal effects on the growth of the primary tumor in each 4-week-old mouse. The growth of the primary tumor was monitored by measuring its diameter every day, and the number of days until the tumor size reached 7 mm in diameter in the footpad was counted when the tumorbearing leg was amputated. (B) Mortality of mice due to the injection of the indicated agents after amputation. The greater survival rate of the MI-18 mice is probably because MI-18 effectively inhibited the metastasis of BL6 cells and caused these mice to be healthier.
Oleamide blocks metastasis
Thus, the effect of the newly synthesized drugs on other components of the membrane might also be examined. Nevertheless, these observations suggest that the safety of any future anti-metastatic drugs that are based on blocking Cx26 may rely on their ability to specifically inhibit Cx26.
Putative anti-Cx26 drugs could have broader clinical applicability if Cx26 is over-expressed in a variety of human cancers. We showed previously that Cx26 expression is enhanced in the invasive population of human melanoma tissues, as measured by immunostaining (7) . In these cases, the original nonmigrating cancer cells displayed very low or almost no expression of Cx26. This observation is consistent with the previous proposal that Cx26 may be a tumor suppressor and the other reports that Cx26 expression is very low in most cancer cells (32--34) . We have also found that in the high metastatic group of human lung squamous cell carcinomas, Cx26 expression is often enhanced to the level seen on BL6 cells, whereas the low and moderate metastatic groups generally expressed Cx26 at lower levels than F10 cells (Ito et al., unpublished observations). Moreover, it has been reported that human breast cancer tissues show enhanced Cx26 expression, which is probably due to the fact that these tissues consisted of highly metastatic populations of cancer cells (25) . By western analysis, we reported previously that a large amount of Cx26 was detected in BL6 cells, but very little Cx26 was detected in F10 cells (7) . We also reported that expressions of other connexins (Cx32, Cx37, Cx40, Cx43) were detected neither in BL6 nor F10 cells (7). Thus, it seems that many cancer cells can be classified into two groups, namely, poor Cx26-expressing F10-types that are unable to spontaneously metastasize, and high Cx26-expressing BL6-types that can potently metastasize spontaneously. Notably, many of the previous immunostaining observations of Cx26 expression in clinical cancer tissues did not focus on the BL6-type of cancer cells (17,22,18--21) . Consequently, it is possible that careful examination of clinical samples for augmented Cx26 expression may reveal cancer cells that may be the highly metastatic BL6-type of cancer cells.
Why Cx26?
To develop more potent anti-metastatic inhibitors in the future, it is important to understand why Cx26 over-expression promotes highly efficient spontaneous metastasis, and which step(s) MI-18 blocks in the process of metastasis development. In our previous study, we showed that BL6 cells communicated with endothelial cells via Cx26 (7). Interestingly, there was a strong correlation between the competence of F10 or BL6 cells to couple with endothelial cells and to metastasize. Based on these findings, we supposed that Cx26 might play a role in intravasations and extravasations of tumor cells in the process of metastasis development. Nedergaard and colleagues (35, 36) presented another example of gap junction formation between tumor cells and host cells. They showed that glioma cells formed gap junction directly with glia cells in vivo, and that gap junction-competent glioma cells were more invasive than gap junction-incompetent glioma cells. They suggested that formation of gap junction between glioma cells and the surrounding glia cells might result in a phenotypic transformation of glia cells that contributes to the susceptibility of surrounding tissues to glioma invasion (36) . Alternatively, signals related through gap junction channels might regulate and direct the mobility of invading glioma cells. Glioma cells, characterized by their diffuse infiltration into surrounding brain tissue, are coupled with glia cells, while melanoma cells, characterized by a high incidence of metastasis, are coupled with endothelial cells (7) . Although which connexins on endothelial cells could form gap junction with Cx26 on melanoma cells is still unknown, MI-18 might block the formation of such a heterologous gap junction, and, as a result, might inhibit the development of metastasis of melanoma cells. Taken together, we propose here the following working hypothesis of why Cx26 promotes spontaneous metastasis. For cancer cells to metastasize to other organs via the blood flow, it is essential that they first establish themselves on vascular endothelial cells within the organ in question. In many cases, these may be the capillary endothelial cells of the lung, which is where the metastasis of many cancers occurs. If the cancer cells that have detached themselves from the primary tumor and now float in the blood flow lack enough connexin to form appropriate gap junctions, they may be washed away by the blood flow and thus fail to establish themselves. On the other hand, if the cancer cells are equipped with enough Cx26, they may be able to form gap junctions with the endothelial cells. This in effect may tether them to the endothelium and provide them with a foothold from which they can invade the surrounding tissue. The connexin isoforms that are predominantly expressed by vascular endothelial cells are Cx37 and Cx40 (37) . It may be that the gap junctions that are formed between Cx26 and Cx37/Cx40 are unusually stable and difficult to break and thus are able to prevent the washing away of the cancer cells by the blood flow. This notion remains to be tested. MI-18 may inhibit the formation of this unusual gap junction by changing the properties of the plasma membrane of the capillary endothelial cells so that the gap junctions between Cx26 and Cx37/Cx40 become unstable. Thus, we surmise that MI-18 inhibits the establishment of cancer cells on capillary endothelial cells, thereby inhibiting their invasion and metastasis. It also remains to be elucidated why, unlike Cx26, over-expression of Cx32 in F10 cells did not promote their spontaneous metastasis (7) . These issues will be tested in our future experiments using HeLa cells expressing human Cx26, Cx32, Cx37, Cx40, Cx43 or Cx45, respectively.
Cancer stem cell and matrix metalloproteinases (MMPs) It may be notable that only one mouse showed no MI-18 effect on metastasis ( Figure 5 ). This might provide a good example for the recent proposal of 'cancer stem cell' hypothesis (38, 39) . This was proposed based on the observation that only a rare and phenotypically distinct subset of cells has the capacity to significantly proliferate and form new tumors. The microenvironment may cause the cancer stem cell to partially differentiate, so that any treatment might affect only one of the two classes of tumor cells, namely, the cancer stem cell and the partially differentiated tumor cells. This hypothesis might apply to many tumors including the highly metastatic cells like BL6.
Many of the anti-metastatic drugs aim to inhibit the invasion of cancer cells. MMPs are good targets of anti-metastatic drugs because they are fundamental to extracellular matrix (ECM) turnover, which plays an active role in tumor invasion and metastasis (40, 41) . Tissue inhibitors of metalloproteinases, which play a critical role in ECM homeostasis by regulating the activity of the MMPs, are known to be effective in blocking the metastasis of various cancer cells (42) . However, the metastasis assays that are used in many of these studies are based on experimental metastasizing cells, which may explain why the pharmaceutical inhibitors of MMPs do not inhibit spontaneous metastasis very well and the clinical trials with these drugs have proved disappointing (43) .
To our knowledge, MI-18 is the most potent inhibitor of spontaneous BL6 melanoma metastasis that has yet been reported. As proposed above, MI-18 may inhibit the establishment of BL6 cells on vascular endothelium and thus inhibit the invasiveness of BL6 cells. Since MMP plays a pivotal role in the invasion of cancer cells into and out of the vascular endothelial cells, a combination of these two drugs may be very effective in blocking the clinical spontaneous metastasis of cancer cells in general.
